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Treatment of hepatocellular carcinoma (HCC) with autologous formalin-fixed tumor vaccine after primary resection
has been shown to suppress the recurrence of hepatitis B virus-associated HCC, but the effect of this treatment on
hepatitis C virus (HCV)-related disease has not yet been clarified. Here, we report a case of a patient with repeat
recurrent HCC that was associated with HCV who had endured 29 episodes of HCC recurrence despite a variety of
therapy using conventional methods. Finally, treatment with a single course of autologous formalin-fixed tumor
vaccine resulted in suppression of potential further re-recurrence of HCC for more than 43 months without any
additional treatment.
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Recurrence of hepatocellular carcinoma (HCC) is highly
frequent despite curative resection. In a randomized clin-
ical trial, treatment with autologous formalin-fixed
tumor vaccine (AFTV) after resection of the mono-
centric primary HCC reduced the risk of recurrence by
81% (P= 0.01) and prolonged median overall survival
time (P= 0.01) in patients with hepatitis B virus (HBV)-
associated HCC [1]. However, we had no clear clinical
data on the effect of AFTV on hepatitis C virus (HCV)-
related HCC. Here, we report a case of a patient with re-
peat recurrent HCC that was associated with hepatitis C
virus (HCV) who had been unsuccessfully treated 29
times with a variety of conventional methods and
endured frequent episodes of recurrent disease. Finally,
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reproduction in any medium, provided the orresulted in suppression of potential re-recurrence of
HCC for more than 43 months.
Case presentation
A seventy-year-old man visited our clinic on June 10,
2008, and presented us with his twenty-nine-treatment
history of HCC over a seven-year period as shown in
Table 1, although the precise doses of chemotherapeutics
were not recorded. Before the first treatment, he was hos-
pitalized in 1964 with acute hepatitis and was subsequently
found to be an anti-HCV antibody carrier in 1993. Since
then, he had been treated with interferon-alpha (IFNa) and
monoammonium glycyrrhizinate. However, in October
1993, it was found that he had developed hepatocellular
carcinoma (HCC) in S8 of the liver. As therapy for the
HCC, multiple conventional treatments had been applied,
such as transarterial embolization (TAE), acetic acid injec-
tion, radiofrequency ablation (RFA), surgical resection,
transcatheter hepatic artery infusion chemotherapy (TAI)
with epirubicin, percutaneous ethanol injection therapy
(PEIT), and microwave tumor coagulation (MTC). The
first surgery was carried out in November 2004 toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Treatments for recurrent tumors of the present case before the AFTV injection
Treatment number Year. Month Treatments
1 2001.09 TAE to the 5 cm primary tumor in S8
2 2002.02-03 TAE to recurrent tumor
3, 4, 5 2002.11-12 Acetic acid injection, three times; no effect
6, 7 2003.09 TAE + RFA; tumor shrinkage
8 2004.08 TAE, no effect
9 2004.11 First surgical resection; incomplete resection
10 2004.12 TAI with epirubicin
11 2005.02 TAE for portal vein tumor thrombosis (Vp4)
12, 13, 14, 15 2005.03-07 Chemotherapy with 5FU and IFNa, preliminary course + three courses; no change
16 2005.09 Second surgical resection of portal vein tumor (Vp4)
17, 18, 19 2006.01-05 Chemotherapy with 5FU and IFNa, three courses
20 2006.06 TAE in S7
21 2006.10-11 Chemotherapy with 5FU and IFNa, an additional course
22, 23, 24 2007.02 MTC, PEIT, lipiodol embolization to the recurrent HCC in S7
25, 26 2007.03 RFA+ PEIT; no effect
27 2007.05 Chemotherapy with 5FU and IFNa, an additional course
28 2007.08 TAE for 1.2 cm tumor in S7; no effect
29 2007.11 Third surgical resection after thoracotomy and partial thoracic diaphragm removal
5FU, 5-fluorouracil; IFNa, interferon-alpha; HCC, hepatocellular carcinoma; MTC, microwave tumor coagulation; PEIT, percutaneous ethanol injection therapy; RFA,
radiofrequency ablation; TAE, transarterial embolization; TAI, transcatheter hepatic artery infusion chemotherapy.
The above treatments were carried out at three different institutions prior to presentation at our clinic and were recorded by the patient himself without precise
descriptions. After the 29th treatment, a single course of AFTV injection [5] was initiated in July 2008 with no further treatment.
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During the second surgery in September 2005, 350 g of
the left lobe of the liver was removed to resect a portal
vein tumor (Vp4). Further chemotherapy with the so-
called FAIT protocol (5-fluorouracil (5FU) plus IFNa)
[2-4] was also performed in a clinical trial, and periph-
eral blood alpha-fetoprotein (AFP) level decreased from
14.2 to 6 ng/ml for six months. However, seven months
after the second surgery, the CT image showed recur-
rent tumors in S7, and the AFP level increased rapidly
to 20 ng/ml. Conventional treatments (Table 1) were in-
effective and were followed by repeated regrowths of
HCC in S7. Further, AFP level increased from 1,143 to
41,958 ng/ml between July 13 and November 21, 2007
(Figure 1). The third aggressive operation was performed
together with thoracotomy and partial thoracic dia-
phragm removal in November 26, 2007, and the tumor
was successfully resected (Figure 2a). Pathological exam-
ination revealed portal vein tumor thrombi (Figure 2b).
The AFP level rapidly decreased to 7 ng/ml by March
6, 2008, where it maintained level for a month, but
slightly increased to 8 ng/ml by May 2, 2008.
Thereafter, the patient strenuously insisted to be trea-
ted with autologous formalin-fixed tumor vaccine
(AFTV) at our clinic. AFTV was prepared as previously
reported [5] with four paraffin-embedded HCC piecesderived from the third resection. A single course of
AFTV therapy consisted of (i) first, a delayed-type hyper-
sensitivity (DTH) test with the fixed HCC fragments but
no immunoadjuvant, which was initiated 48 hours before
the first AFTV injection, (ii) intradermal injection of
AFTV, two weeks apart and up to three times, and (iii) a
second DTH test performed two weeks after the last
AFTV injection according to the schedule described [1].
The DTH test was negative before the first AFTV injec-
tion and became positive (11 × 12.5 mm erythema and 5
× 5 mm induration) after the third AFTV injection as
evaluated on August 25, 2008. We found no adverse
effects except for small local erythema at the AFTV in-
jection sites. We also observed his blood HCV-RNA
level, 5.7 log IU/mL.
Without any further adjuvant therapy, the patient
maintained low AFP levels (6 to 8 ng/ml) for more than
43 months (Figure 1). The patient remains well with no
evidence of metastasis or local recurrence.
Complete suppression of HCC recurrence is known to
be difficult to attain with conventional treatment meth-
ods. In the present case, eight different therapies
(Table 1) had been applied with no success, since
repeated recurrence of the HCC in S7 of the liver oc-
curred before the AFTV therapy. Although the third sur-
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Figure 1 Alpha-fetoprotein (AFP) levels after the 11th treatment (TAE). Autologous formalin-fixed tumor vaccine (AFTV) treatment, which
consisted of a single course of vaccine injection, was initiated in July 2008 with no further treatment. ‘Chemo’ in the figure indicates
chemotherapy with 5-fluorouracil (5FU) and IFNa (the so-called FAIT protocol) [2-4], which was administered as treatments number 12 to 15, 17 to
19, 21, and 27 as shown in Table 1.
Inui and Ohno World Journal of Surgical Oncology 2012, 10:144 Page 3 of 4
http://www.wjso.com/content/10/1/144AFP levels from 41,958 to 7 ng/ml, it was highly likely
that the potentially remaining HCC cells were not com-
pletely removed, since multiple portal vein tumor
thrombi have been observed (Figure 2b). Also, HCC re-
currence rates in patients of positive HCV-RNA were
known very high, such as 55.3% at the third year and
72.2% at the fifth year after surgical resection [6]. In this
case, recurrent tumors in S7 were found seven months
after the second operation, which had decreased the
AFP level down to 6 ng/ml. Therefore, we consider that,Figure 2 Re-recurrent tumor in S7 removed during the third resection
diaphragm. (b) H & E-stained section of the 3 cm re-recurrent carcinoma. Pafter the third operation, AFTV treatment successfully
suppressed potential further HCC recurrence in this
patient.Conclusions
The findings from the present case suggest that AFTV
treatment suppressed potential further HCC recurrence
for more than 43 months after the third resection and that
AFTV is a feasible therapy for further large-scale clinical. (a) The resected 3 cm re-recurrent carcinoma with partial thoracic
ortal vein thrombi were observed.
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with not only HBV but also HCV after surgical resection.
Consent
Written informed consent in English and Japanese has
been obtained from the patient for publication of this
case report and any accompanying images.
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